Activation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis

Cited by (254)

Items 101–200 of 254

1. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?
   Ting Chen, Jessica A. George, Christopher Taylor · 2006 · Anti-Cancer Drugs
2. Quantitative Phospho-Proteomic Profiling of Hepatocyte Growth Factor (HGF)-MET Signaling in Colorectal Cancer
   Shawna Leslie Organ, Jiefei Tong, Paul P. Taylor, Jonathan R. St‐Germain, Roya Navab, Michael F. Moran, Ming‐Sound Tsao · 2011 · Journal of Proteome Research
3. Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic.
   Scott Kopetz · 2007 · PubMed Central
4. Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells
   Hee Boong Park, Vita Golubovskaya, Lihui Xu, Xihui Yang, Jin Woo Lee, Sean Scully, Rolf J. Craven, William G. Cance · 2004 · Biochemical Journal
5. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
   Perez, Marco, Lucena-Cacace, Antonio, Marín-Gómez, Luis Miguel, Padillo-Ruiz, Javier, Robles-Frias, Maria Jose, Saez, Carmen, Garcia-Carbonero, Rocio, Carnero, Amancio · 2016 · Oncotarget
6. ADAM17-regulated CX3CL1 expression produced by bone marrow endothelial cells promotes spinal metastasis from hepatocellular carcinoma
   Chi Chin Sun, Annan Hu, Shengxing Wang, Bo Tian, Libo Jiang, Yun Liang, Houlei Wang, Jian Dong · 2020 · International Journal of Oncology
7. The long road to colorectal cancer therapy: Searching for the right signals
   Frédéric Hollande, Julie Pannequin, DOMINIQUE BRESSION · 2010 · Drug Resistance Updates
8. Brain Metastases from Colorectal Cancer: Microenvironment and Molecular Mechanisms
   Yi-Wen Zang, Xiaodong Gu, Jianbin Xiang, Zongyou Chen · 2012 · International Journal of Molecular Sciences
9. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer
   Michael S. Lee, Scott Kopetz · 2015 · Clinical Colorectal Cancer
10. Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment
    Leena Heiska, Maria Melikova, Fang Zhao, Ichiko Saotome, Andrea I. McClatchey, Olli Carpén · 2011 · Oncogene
11. The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility
    Cyril H. Benes, George Poulogiannis, Lewis C. Cantley, Stephen P. Soltoff · 2011 · Oncogene
12. Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells
    Ling Ma, Jia Wei, Gloria H. Su, Jiayuh Lin · 2019 · Cancer Biology & Therapy
13. Srcasm Corrects Fyn-induced Epidermal Hyperplasia by Kinase Down-regulation
    Weijie Li, Christine M. Marshall, Lijuan Mei, Joel M. Gelfand, John T. Seykora · 2006 · Journal of Biological Chemistry
14. Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation
    Xiuquan Ma, Luxi Zhang, Jiangning Song, Elizabeth V. Nguyen, Rachel S. Lee, Samuel J. Rodgers, Fuyi Li, Cheng Huang, Ralf B. Schittenhelm, Howard Chan et al. · 2019 · Nature Communications
15. Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention
    Anshu Wadhawan, Christopher R. Smith, Robert I. Nicholson, Peter J. Barrett-Lee, Stephen Hiscox · 2010 · Cancer Treatment Reviews
16. Spatial cycles mediated by UNC119 solubilisation maintain Src family kinases plasma membrane localisation
    Antonios D. Konitsiotis, Lisaweta Roßmannek, Angel Stanoev, Malte Schmick, Philippe I. H. Bastiaens · 2017 · Nature Communications
17. Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
    Niamh McGivern, Aya El Helali, Paul B. Mullan, Iain A. McNeish, D. Paul Harkin, Richard D. Kennedy, Nuala McCabe · 2017 · Oncotarget
18. Anti-GPR56 monoclonal antibody potentiates GPR56-mediated Src-Fak signaling to modulate cell adhesion
    Treena Chatterjee, Sheng Zhang, Tressie A. Posey, Joan Jacob, Ling Wu, Wangsheng Yu, Liezl E. Francisco, Qingyun J. Liu, Kendra S. Carmon · 2021 · Journal of Biological Chemistry
19. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer
    Paolo Ceppi, Ida Rapa, Marco Lo Iacono, Luisella Righi, Jessica Giorcelli, Marisa Pautasso, Andrea Billè, Francesco Ardissone, Mauro Giulio Papotti, Giorgio V. Scagliotti · 2011 · International Journal of Cancer
20. Improve discrimination power of serum markers for diagnosis of cholangiocarcinoma using data mining-based approach
    Sirorat Pattanapairoj, Atit Silsirivanit, Kanha Muisuk, Wunchana Seubwai, Ubon Cha’on, Kulthida Vaeteewoottacharn, Kanlayanee Sawanyawisuth, Danaipong Chetchotsak, Sopit Wongkham · 2015 · Clinical Biochemistry
21. Defining the “Metastasome”: Perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences
    Heike Allgayer, Jörg Hendrik Leupold, Nitin Patil · 2019 · Seminars in Cancer Biology
22. New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors
    Bernard C. Barlaam, Mike Fennell, Hervé Germain, Tim Green, Laurent François Hennequin, Rémy Morgentin, Annie Olivier, Patrick A. Plé, Michel Vautier, Gerard F. Costello · 2005 · Bioorganic & Medicinal Chemistry Letters
23. Roles of Hormones and Signaling Molecules in Describing the Relationship Between Obesity and Colon cancer
    Angelos K. Sikalidis, Behzad Varamini · 2011 · Pathology & Oncology Research
24. Activation of Src and transformation by an RPTPα splice mutant found in human tumours
    Huang, Jian, Yao, Ling, Xu, Rongting, Wu, Huacheng, Wang, Min, White, Brian S, Shalloway, David, Zheng, Xinmin · 2011 · The EMBO Journal
25. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
    John H. Strickler, Shannon J. McCall, Andrew B. Nixon, John C. Brady, Herbert Pang, Christel N. Rushing, Allen Lee Cohn, Alexander Starodub, Christy Arrowood, Sherri T. Haley et al. · 2013 · Investigational New Drugs
26. Tom1l2 hypomorphic mice exhibit increased incidence of infections and tumors and abnormal immunologic response
    Santhosh Girirajan, Paula M. Hauck, Stephen R. Williams, Christopher N. Vlangos, Barbara B. Szomju, Sara Solaymani-Kohal, Philip D. Mosier, Kimber L. White, Kathleen L. McCoy, Sarah H. Elsea · 2008 · Mammalian Genome
27. Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells
    Calley L. Hirsch, Erin Smith-Windsor, Keith Bonham · 2005 · International Journal of Cancer
28. Increases in c-Src Expression Level and Activity Do Not Promote the Growth of Human Colorectal Carcinoma Cells In Vitro and In Vivo
    Welman, Arkadiusz, Cawthome, Christopher, Ponce-Perez, Lourdes, Barraclough, Jane, Danson, Sarah, Murray, Stephen, Cummings, Jeff, Allen, Terry D., Dive, Caroline · 2006 · Neoplasia
29. Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters
    Christopher J. Morrow, Mohammad A. Ghattas, Christopher G. Smith, Heinz Bönisch, Richard A. Bryce, D. Mark Hickinson, Tim P. Green, Caroline Dive · 2010 · Cancer Research
30. Antitumor Activity of miR-1280 in Melanoma by Regulation of Src
    Vera Sun, Wen Zhou, Mehdi Nosrati, Shahana Majid, Suresh Thummala, David de Semir, Vladimir Bezrookove, Sébastien M. de Feraudy, Liane Chun, Dirk Schadendorf et al. · 2014 · Molecular Therapy
31. Phase I study of dasatinib (BMS‐354825) in Japanese patients with solid tumors
    Shunji Takahashi, Masaki Miyazaki, Isamu Okamoto, Yoshinori Ito, Kyoji Ueda, Taku Seriu, Kazuhiko Nakagawa, Kiyohiko Hatake · 2011 · Cancer Science
32. p70S6K is regulated by focal adhesion kinase and is required for Src-selective autophagy
    Emma Sandilands, Christina Schoenherr, Margaret C. Frame · 2015 · Cellular Signalling
33. By moonlighting in the nucleus, villin regulates epithelial plasticity
    Srinivas Patnaik, Sudeep P. George, Eric Pham, Swati Roy, Kanchan Singh, John Martin Mariadason, Seema Khurana · 2015 · Molecular Biology of the Cell
34. Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation
    Pieter de Heer, Margaretha M. Koudijs, Cornelis J.�H. van de Velde, Remco I.J.M. Aalbers, R.A.E.M. Tollenaar, Hein Putter, J. Morreau, Bob van de Water, Peter J.K. Kuppen · 2008 · European Journal of Surgical Oncology
35. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
    Meiyu Dong, Lori P. Rice, Sharon E. Lepler, Christine Pampo, Dietmar W. Siemann · 2010 · PubMed
36. The comparisons of prognostic indexes using data mining techniques and Cox regression analysis in the breast cancer data
    Mevlut Türe, Füsun Tokatlı, İmran Kurt Ömürlü · 2008 · Expert Systems with Applications
37. Utilization of Fluorescence Polarization and Time Resolved Fluorescence Resonance Energy Transfer Assay Formats for SAR Studies: Src Kinase as a Model System
    Miki N. Newman, Serene Josiah · 2004 · SLAS DISCOVERY
38. A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells
    Yu Ling, Yeye Kuang, Linlin Chen, Weifeng Lao, Yao-Ru Zhu, Le-Qi Wang, Da Wang · 2017 · Oncotarget
39. Genetic unraveling of colorectal cancer
    Sabha Rasool, Vamiq Rasool, Tahira Naqvi, Bashir Ahmad Ganai, Bhahwal Ali Shah · 2014 · Tumor Biology
40. Anti-metastatic Potential of Natural Triterpenoid Cucurbitacin B Against Cholangiocarcinoma Cells by Targeting Src Protein
    Putthaporn Kaewmeesri, Piman Pocasap, Veerapol Kukongviriyapan, Auemduan Prawan, Sarinya Kongpetch, Laddawan Senggunprai · 2022 · Integrative Cancer Therapies
41. Clinical significance of Src expression and activity in human neoplasia.
    Nikolaos A. Chatzizacharias, Gregory P. Kouraklis, Constantinos Giaginis, Stamatios E Theocharis · 2012 · PubMed
42. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells
    Min Shi, Bing-xiang Lou, Jun Ji, Hailong Shi, Chenfei Zhou, Yingyan Yu, Bingya Liu, Zhenggang Zhu, Jun Zhang · 2013 · Cancer Chemotherapy and Pharmacology
43. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
    Tanja Trarbach, Beate S. Schultheis, Thomas Christoph Gauler, Vesile Schneider, Dirk Strumberg, Wilfried Eberhardt, Stephanie Le Scouiller, Marcelo Marotti, Kathryn H. Brown, Joachim Drevs · 2011 · Investigational New Drugs
44. Contribution of phosphoproteomics in understanding SRC signaling in normal and tumor cells
    Audrey Sirvent, Serge Urbach, Serge Roche · 2014 · PROTEOMICS
45. YES oncogenic activity is specified by its SH4 domain and regulates RAS/MAPK signaling in colon carcinoma cells.
    Fanny Dubois, Cédric Leroy, Valérie Simon, Christine Bénistant, Serge Roche · 2015 · Europe PMC (PubMed Central)
46. Prognostic relevance of Src activation in stage II-III colon cancer
    Martínez-Pérez, Julia, Lopez-Calderero, Iker, Saez, Carmen, Benavent, Marta, Limon, Maria L., Gonzalez-Exposito, Reyes, Soldevilla, Beatriz, Riesco-Martínez, Maria Carmen, Salamanca, Javier, Carnero, Amancio et al. · 2017 · Human Pathology
47. Kinetics characterization of c-Src binding to lipid membranes: Switching from labile to persistent binding
    Anabel‐Lise Le Roux, Maria Antònia Busquets, Francesc Sagués, Miquel Pons · 2015 · Colloids and Surfaces B Biointerfaces
48. BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer
    Yoshifumi Shimada, Yusuke Muneoka, Masayuki Nagahashi, Hiroshi Ichikawa, Yosuke Tajima, Yuki Hirose, Takuya Ando, Masato Nakano, Jun Sakata, Hitoshi Kameyama et al. · 2019 · Scientific Reports
49. Suppression of E-Cadherin Function Drives the Early Stages of Ras-Induced Squamous Cell Carcinoma through Upregulation of FAK and Src
    Addy Alt‐Holland, Adam G. Sowalsky, Yonit Szwec-Levin, Yulia Shamis, Harold Hatch, Larry A. Feig, Jonathan A. Garlick · 2011 · Journal of Investigative Dermatology
50. Downregulation of miR-654-3p in Colorectal Cancer Indicates Poor Prognosis and Promotes Cell Proliferation and Invasion by Targeting SRC
    Haoran Zhang, Zhanlong Shen, Yushi Zhou, Zhen Zhang, Quan Wang, Mengmeng Zhang, Kewei Jiang, Shan Wang, Yingjiang Ye, Bo Wang · 2020 · Frontiers in Genetics
51. Staging of Colorectal Cancer: Past, Present, and Future
    Janet K. Horton, Joel E. Tepper · 2005 · Clinical Colorectal Cancer
52. MicroRNA-3607 inhibits the tumorigenesis of colorectal cancer by targeting DDI2 and regulating the DNA damage repair pathway
    Lei Lei, Xiaojuan Zhao, Shuzhen Liu, Q. Cao, Bianbian Yan, Jin Yang · 2019 · Apoptosis
53. Improved Angiostatic Activity of Dasatinib by Modulation with Hydrophobic Chains
    Emilia Păunescu, Catherine M. Clavel, Patrycja M. Nowak-Sliwinska, Arjan W. Griffioen, Paul J. Dyson · 2015 · ACS Medicinal Chemistry Letters
54. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer
    Scott Kopetz, Van Karlyle Morris, Nila U. Parikh, Michael James Overman, Zhi-Qin Jiang, Dipen Maheshbhai Maru, Paul Elvin, Gary E. Gallick · 2014 · BMC Cancer
55. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results
    Dana Backlund Cardin, Laura Williams Goff, Emily Chan, Jennifer G. Whisenant, Gregory Dan Ayers, Naoko Takebe, Lori R. Arlinghaus, Thomas E. Yankeelov, Jordan D. Berlin, Nipun B. Merchant · 2017 · Investigational New Drugs
56. The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers
    Robert J. Jones, Tamsin Boyce, Michael Fennell, Vivien N. Jacobs, Francesco Pinto, Emma L. Duffield, Glen Clack, Tim Green, John D. Kelly, John Robertson · 2007 · Cancer Chemotherapy and Pharmacology
57. 3D-QSAR study of Chk1 kinase inhibitors based on docking
    Lingzhou Zhao, Yongjuan Liu, Shiyuan Hu, Huabei Zhang · 2012 · Journal of Molecular Modeling
58. Advancing Src kinase inhibition: From structural design to therapeutic innovation - A comprehensive review
    Yifeng Su, Kun Zhu, Jiahao Wang, Boyan Liu, Yue Chang, Degui Chang, Yaodong You · 2025 · European Journal of Medicinal Chemistry
59. Fas Versatile Signaling and Beyond: Pivotal Role of Tyrosine Phosphorylation in Context-Dependent Signaling and Diseases
    Krittalak Chakrabandhu, Anne‐Odile Hueber · 2016 · Frontiers in Immunology
60. Molecular regulation of an invasion-related molecule – options for tumour staging and clinical strategies
    Heike Allgayer · 2006 · European Journal of Cancer
61. Single molecule fluorescence reveals dimerization of myristoylated Src N‐terminal region on supported lipid bilayers
    Anabel‐Lise Le Roux, Bruno Castro, Erik T. Garbacik, M.F. Garcia Parajo, Miquel Pons · 2016 · ChemistrySelect
62. Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
    Silvia Schenone, Samantha Zanoli, Chiara Brullo, Emmanuele Crespan, Giovanni Maga · 2008 · Current Drug Therapy
63. Global Phosphotyrosine Proteomics Identifies PKCδ as a Marker of Responsiveness to Src Inhibition in Colorectal Cancer
    Eliot T. McKinley, Huiling Liu, William Hayes McDonald, Weifeng Luo, Ping Zhao, Robert J. Coffey, Steven K. Hanks, H. Charles Manning · 2013 · PLoS ONE
64. CEP55 Positively Affects Tumorigenesis of Esophageal Squamous Cell Carcinoma and Is Correlated with Poor Prognosis
    Shumei Yan, Lili Liu, Wan-Yi Gu, Liyun Huang, Yi Yang, Yuhua Huang, Rongzhen Luo · 2021 · Journal of Oncology
65. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways
    Yi‐Hua Lai, Min-Hsuan Chen, Sih-Yin Lin, Sheng-Yi Lin, Yung-Hao Wong, Sung‐Liang Yu, Huei‐Wen Chen, Chih-Hsin Yang, Gee‐Chen Chang, Jeremy J.W. Chen · 2015 · Oncotarget
66. 4-Hydroxynonenal activates Src through a non-canonical pathway that involves EGFR/PTP1B
    Hong-Qiao Zhang, H. Forman · 2015 · Free Radical Biology & Medicine
67. CSK-mediated signalling by integrins in cancer
    Horacio Maldonado, Lisette Leyton · 2023 · Frontiers in Cell and Developmental Biology
68. High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer
    Narendra Padhan, Torbjörn E. M. Nordling, Magnus Sundström, Peter Åkerud, Helgi Birgisson, Peter Nygren, Sven Nelander, Lena Claesson · 2016 · BMC Cancer
69. Small-Molecule Inhibition of the UNC-Src Interaction Impairs Dynamic Src Localization in Cells
    Guillaume Garivet, Walter Hofer, Antonios D. Konitsiotis, Christian Klein, Nadine Kaiser, Tom Mejuch, Eyad K. Fansa, Rania Alsaabi, Alfred Wittinghofer, Philippe I. H. Bastiaens et al. · 2019 · Cell chemical biology
70. Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment
    John C. Dawson, Alison F. Munro, Kenneth Macleod, Morwenna Muir, Paul Timpson, Robert J. Williams, Margaret C. Frame, Valerie G. Brunton, Neil O. Carragher · 2021 · Molecular Oncology
71. A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424
    Victoria K. Woodcock, Sally Clive, Richard H. Wilson, Vicky M. Coyle, Michael R.L. Stratford, Lisa K. Folkes, Richard Eastell, Claire M. Barton, Paul S. Jones, Shamim Kazmi-Stokes et al. · 2018 · British Journal of Cancer
72. Combining statistical techniques to predict postsurgical risk of 1-year mortality for patients with colon cancer
    Inmaculada Aróstegui, Nerea González, Nerea Fernández‐de‐Larrea, Santiago Lázaro, Marisa Baré, Maximino Redondo, Cristina Sarasqueta, Susana García‐Gutiérrez, José María Quintana · 2018 · Clinical Epidemiology
73. Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?
    Teresa Troiani, Erika Martinelli, Floriana Morgillo, Anna Capasso, Anna Giulia Nappi, Vincenzo Sforza, Fortunato Ciardiello · 2012 · Therapeutic Advances in Medical Oncology
74. Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation
    Thanh Kieu Huynh, Chien-Yi Ho, Chi-Hua Tsai, Chien‐Kuo Wang, Yun‐Ju Chen, Da‐Tian Bau, Chih‐Yen Tu, Tzong-Shiun Li, Wei‐Chien Huang · 2019 · International Journal of Molecular Sciences
75. Src Family Kinases as Regulators of Angiogenesis: Therapeutic Implications
    Donald P. Lesslie, Gary E. Gallick · 2005 · Current Cancer Therapy Reviews
76. Identification of Important Invasion-Related Genes in Non-functional Pituitary Adenomas
    Harish R. Joshi, Basavaraj Mallikarjunayya Vastrad, Chanabasayya Mallikarjunayya Vastrad · 2019 · Journal of Molecular Neuroscience
77. Novel Targets for Anticancer Treatment Development in Colorectal Cancer
    Teresa Mercade Macarulla, Francisco Javier Ramos, Jaume Capdevila, Cristina Saura, Josep M. Tabernero · 2006 · Clinical Colorectal Cancer
78. Kinase Inhibitors in Cancer
    Andrew A. Mortlock, Kevin M. Foote, Jason G. Kettle, Brian M. Aquila · 2014 · Elsevier eBooks
79. Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells
    Jinyan Shen, Li Li, Tao Yang, Niuliang Cheng, Gongqin Sun · 2019 · Molecules
80. Novel approaches in oncology at AstraZeneca
    Catherine Wheeler, Trevor C. Stephens, Kate Byth, Tim Green, Stephen R. Wedge, David C. Blakey, Andrew M. Hughes · 2003 · European Journal of Cancer Supplements
81. Novel Bioluminescent Activatable Reporter for Src Tyrosine Kinase Activity in Living Mice
    Weibing Leng, Dezhi Li, Liang Chen, Hongwei Xia, Qiulin Tang, Baoqin Chen, Qiyong Gong, Fabao Gao, Feng Bi · 2016 · Theranostics · Retracted
82. AHA1 regulates cell migration and invasion via the EMT pathway in colorectal adenocarcinomas
    Dasom Kim, Ji Wook Moon, Dong Hwa Min, Eun Sun Ko, Bokyung Ahn, Eun Sun Kim, Ji-Yun Lee · 2021 · Scientific Reports
83. Synthesis, biological evaluation and docking studies of 4-amino-tetrahydroquinazolino[3,2-e]purine derivatives
    Valérie Verones, Nathalie Flouquet, Amaury Farce, Pascal Carato, Stéphane Léonce, Bruno Pfeiffer, Pascal Berthelot, Nicolas Lebègue · 2010 · European Journal of Medicinal Chemistry
84. Comparative role of acetylation along c-SRC/ETS1 signaling pathway in bone metastatic and invasive mammary cell phenotypes
    Paola Bendinelli, Paola Maroni, Emanuela Matteucci, Maria Alfonsina Desiderio · 2011 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
85. 3D-QSAR study of c-Src kinase inhibitors based on docking
    Ran Cao, Na Mi, Huabei Zhang · 2009 · Journal of Molecular Modeling
86. Estradiol‐mediated regulation of hepatic iNOS in obese rats: Impact of Src, ERK1/2, AMPKα, and miR‐221
    Anastasija Panić, Julijana Stanimirović, Milan M. Obradovic, Emina M. Sudar-Milovanovic, Milan Perović, Milena Lačković, Nina Petrović, Esma R. Isenović · 2018 · Biotechnology and Applied Biochemistry
87. The modification of Sp3 isoforms by SUMOylation has differential effects on the SRC1A promoter
    Danielle J.P. Ellis, Scott M. Dehm, Keith Bonham · 2006 · Gene
88. FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells
    Betlem Mezquita, Marjorie Reyes‐Farias, Miquel Pons · 2024 · Biomedicine & Pharmacotherapy
89. A FRET-Based Biosensor for the Src N-Terminal Regulatory Element
    Guillermo Iruela, Alejandro Fernández, Amin Sagar, Francisco J. Carvajal, Pau Bernadó, Miquel Pons · 2022 · Biosensors
90. Theoretical Studies of QSAR and Molecular Design on a Novel Series of Ethynyl‐3‐Quinolinecarbonitriles as Src Inhibitors
    Dan Qing Fang, Wen Juan Wu, Rong Zhang, Guo Hua Zeng, KANG CHENG ZHENG · 2012 · Chemical Biology & Drug Design
91. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer
    Yeh Chen Lee, Michael Michael, John Raymond Zalcberg · 2015 · Expert Opinion on Investigational Drugs
92. Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin
    Megan D. Indermaur, Yin Xiong, Siddharth G. Kamath, Todd Boren, Ardeshir Hakam, Robert Michael Wenham, Sachin M. Apte, Johnathan M. Lancaster · 2010 · American Journal of Obstetrics and Gynecology
93. Control of Tyrosine Kinase Signalling by Small Adaptors in Colorectal Cancer
    Rudy Mevizou, Audrey Sirvent, Serge Roche · 2019 · Cancers
94. The new paradigm in the treatment of colorectal cancer: are we hitting the right target?
    Joaquina Celebre Baranda, Stephen K. Williamson · 2007 · Expert Opinion on Investigational Drugs
95. Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer
    Rubio-Cuesta, Beatriz, Carretero-Puche, Carlos, Llamas, Patricia, Sarmentero, Jacinto, Gil-Calderon, Beatriz, Lens-Pardo, Alberto, Antón-Pascual, Beatriz, Rubio-González, Eduardo, Cámara-Jurado, María, Salamanca, Javier et al. · 2025 · British Journal of Cancer
96. Autophagy awakens—the myriad roles of autophagy in head and neck cancer development and therapeutic response
    Samantha T. Bradley, Yong‐Syu Lee, Zafer Gürel, Randall J. Kimple · 2021 · Molecular Carcinogenesis
97. Contact Normalization or Escape from the Matrix
    Harini Krishnan, Gary S. Goldberg · 2015 · Springer eBooks
98. Novel Agents in the Treatment of Metastatic Colorectal Cancer
    Stephen Leong, Wells A. Messersmith, Aik Choon Tan, Sabine Eckhardt · 2010 · The Cancer Journal
99. Synergistic Anti-Tumor Effect of Cisplatin When Combined with an Anti-Src Kinase Integrin-Based Peptide
    Michael Agrez, Madhu B. Garg, Douglas J. Dorahy, Stephen P. Ackland · 2011 · Journal of Cancer Therapy
100. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer
     Zain A. Sobani, Ashwin Shreekant Sawant, Mikram Jafri, Amit Keith Correa, İbrahim Halil Şahin · 2016 · World Journal of Clinical Oncology